Results 1 to 10 of about 1,427,322 (409)

Squamous Cell Carcinoma.

open access: yesCutis, 2023
Cutaneous squamous cell carcinoma (SCC) develops from a malignant tumor of the keratinocytes, eccrine glands, or pilosebaceous units that invades the dermis.
Candrice R Heath, Richard P Usatine
semanticscholar   +4 more sources

Beyond Squamous Cell Carcinoma: Basaloid Squamous Cell Carcinoma of the Esophagus [PDF]

open access: yesCureus, 2021
Basaloid squamous cell carcinoma (BSCC) is a poorly differentiated variant of squamous cell carcinoma (SCC) with distinct morphologic characteristics. Yet, there are no clearly defined guidelines established for management. BSCC in the esophagus is a very rare entity, with the proportion of esophageal BSCC ranging from 0.068% to 11%. This wide range is
Song, Heeyah   +4 more
openaire   +2 more sources

Head and neck squamous cell carcinoma

open access: yesNature Reviews Disease Primers, 2020
Head and neck squamous cell carcinomas (HNSCCs) originate from the mucosal epithelium in the oral cavity, pharynx and larynx, and are caused by viral infection or carcinogen exposure.
Daniel E. Johnson   +5 more
semanticscholar   +2 more sources

Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma

open access: yesMedical Science, 2023
Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies, involving the oral cavity, pharynx, hypopharynx, larynx, nasal cavity, and salivary glands, that together compose the seventh most common cancer diagnosis worldwide.
A. Barsouk   +4 more
semanticscholar   +1 more source

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.

open access: yesNew England Journal of Medicine, 2022
BACKGROUND First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal
Y. Doki   +29 more
semanticscholar   +1 more source

Clinical and Paraclinical Characteristics of Endobronchial Pulmonary Squamous Cell Carcinoma—A Brief Review

open access: yesDiagnostics, 2023
Background: Endobronchial squamous cell carcinoma is one of the most common types of tumors located inside the tracheobronchial tree. Patients often present in advanced stages of the disease, which most often leads to a targeted therapeutic attitude of ...
Radu Serban Matache   +6 more
doaj   +1 more source

Effect of Small-molecule Inhibitor CIL56 on Death of Esophageal Squamous Cell Carcinoma Cells

open access: yesZhongliu Fangzhi Yanjiu, 2023
Objective To investigate the role and mechanism of the small-molecule inhibitor CIL56 in the death of esophageal squamous cell carcinoma cells. Methods SRB method and plate-cloning method were used to detect the effect of CIL56 on the proliferation of ...
CHEN Jiaxing, XU Xiaqing, ZHANG Qi
doaj   +1 more source

Primary Squamous Cell Carcinoma of Submandibular Salivary Gland with Sialo-Cutaneous Fistula: A Rare Case Report [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2015
Malignant tumours of the submandibular salivary glands are rare entities. Most common malignant tumour of submandibular gland is mucoepidermoid carcinoma.
Aditya Atul Kulkarni, Sanjiv S. Thakur
doaj   +1 more source

Squamous Cell Carcinoma [PDF]

open access: yesJAMA Dermatology, 2013
Irregular aggregates of neoplastic keratinocytes arising from the epidermis and invading the dermis.
Jeremy, Davis, Jeremy, Bordeaux
openaire   +2 more sources

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

open access: yesJournal of the American Medical Association (JAMA), 2021
Importance Standard first-line therapy for advanced or metastatic esophageal carcinoma is chemotherapy, but the prognosis remains poor. Camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) showed antitumor activity in previously treated ...
Hui‐yan Luo   +29 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy